Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition

@inproceedings{Bunck2010ExenatideAC,
  title={Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition},
  author={Mathijs C Bunck and Michaela Diamant and Bjorn Eliasson and Anja Corn{\'e}r and Rimma M. Shaginian and R. Heine and Marja-Riitta Taskinen and Hannele Yki-J{\"a}rvinen and Ulf Smith},
  booktitle={Diabetes care},
  year={2010}
}
OBJECTIVE To study the effect of exenatide on body composition and circulating cardiovascular risk biomarkers. RESEARCH DESIGN AND METHODS Metformin-treated patients with type 2 diabetes (N = 69) were randomized to exenatide or insulin glargine and treated for 1 year. Body composition was evaluated by dual-energy X-ray absorptiometry. Additionally, body weight, waist circumference, and cardiovascular biomarkers were measured. RESULTS Treatment with exenatide for 1 year significantly reduced… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Effects of exenatide vs insulin glargine on cardiovascular risk factors in subjects with type 2 diabetes

  • ES Horton, A Cohen, H Gibson, B Lamparello, S Herzlinger, L. McFarland
  • Diabetologia
  • 2009
1 Excerpt

One - Year Treatment With Exenatide Improves Beta - Cell Function , Compared To Insulin Glargine , In Metformin Treated Type 2 Diabetes Patients : A Randomized , Controlled Trial

  • W Kim, JM Egan
  • Diabetes Care
  • 2009

mellitus

  • MC Bunck, M Diamant, +9 authors RJ Heine
  • 2009

Similar Papers

Loading similar papers…